Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BS01 gene therapy in retinitis pigmentosa
NCT04278131Phase 2Recruiting
- Sponsor
- Bionic Sight
- Start
- Feb 2020
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of BS01 in retinitis pigmentosa (RP) (6 cohorts), sponsored by Bionic Sight. Primary endpoint: Primary Safety Outcome at 12 months. Started Feb 2020; status: recruiting.
02
Drugs
BS01
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT04278131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278131.